Search results
Found 65 matches for
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
Alternating vaccines trial expands to include two additional vaccines
COVID-19 Clinical Trials Vaccinology
14 April 2021
Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
UK and EU regulators conclude benefits of vaccination continue to outweigh the risks
COVID-19 Vaccinology
7 April 2021
Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.
AstraZeneca publish primary analysis from US trial of coronavirus vaccine
COVID-19 Vaccinology
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective
COVID-19 Vaccinology
22 March 2021
- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported
Professor Matthew Snape named NIHR Senior Investigator
Awards & Appointments Vaccinology
4 March 2021
Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.
Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests
COVID-19 Research Vaccinology
24 February 2021
The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.
Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK
COVID-19 Research Vaccinology
5 February 2021
A preprint of ongoing work to assess effectiveness of Oxford’s ChAdOx1 coronavirus vaccine shows that the existing vaccine has similar efficacy against the B.1.1.7 ‘Kent’ coronavirus strain currently circulating in the UK to previously circulating variants.
Oxford leads first trial investigating dosing with alternating vaccines
COVID-19 Clinical Trials Vaccinology
4 February 2021
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.
Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium
COVID-19 Vaccinology
26 January 2021
Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.
First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy
COVID-19 Vaccinology
10 December 2020
University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.
Oxford University breakthrough on global COVID-19 vaccine
COVID-19 Vaccinology
23 November 2020
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
Oxford coronavirus vaccine produces strong immune response in older adults
COVID-19 Vaccinology
19 November 2020
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
SIMON Says…
Vaccinology
14 November 2020
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show
COVID-19 Vaccinology
23 September 2020
Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.
There is now clear data on Covid-19 and children: it should be safe to reopen English schools
Parents & Carers Vaccinology
18 August 2020
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Typhoid vaccine project wins Vice-Chancellor award
Awards & Appointments Vaccinology
27 July 2020
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
Ebola vaccine approved for use by the European Commission
Vaccinology
2 July 2020
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
The Duke of Cambridge visits Oxford Vaccine Centre
COVID-19 Vaccinology
26 June 2020
The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
COVID-19 Clinical Trials Vaccinology
15 June 2020
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
Oxford COVID-19 vaccine to begin phase II/III human trials
COVID-19 Clinical Trials Vaccinology
22 May 2020
Oxford Vaccine Group researchers have begun recruiting for the next phase in human trials of a COVID-19 vaccine in human volunteers.